ARTMS

ARTMS specializes in technology that allows for the decentralized production of high-demand medical isotopes using hospital-based cyclotrons. Its primary clients are hospitals, medical imaging centers, pharmaceutical distributors, and radiopharmaceutical companies that operate cyclotrons. The business model centers on selling its proprietary QUANTM Irradiation System (QIS™), related hardware, and single-use consumable targets. This empowers clients to produce isotopes on-site, providing them with control over their supply chain and mitigating risks associated with centralized production, such as shortages and high costs. By upgrading existing cyclotrons, ARTMS offers a cost-effective solution without the need for major new construction.

The company's flagship product is the QUANTM Irradiation System (QIS™), a comprehensive solution that enables the high-yield production of several crucial medical isotopes. The QIS™ consists of an automated pneumatic transfer system, a compact solid target station, and solutions for processing the solid targets. This system is compatible with most commonly installed cyclotrons and can be installed with minimal interruption to daily operations. A key benefit of the technology is its ability to produce large, cost-effective batches of isotopes like Technetium-99m (Tc-99m), Gallium-68 (Ga-68), Zirconium-89 (Zr-89), and Copper-64 (Cu-64). For instance, a single 90-minute run can produce over 100 patient doses of Ga-68 at a fraction of the traditional cost. The process also produces minimal long-lived radioactive waste, addressing significant environmental and disposal concerns associated with reactor-based methods. The technology has received approval from Health Canada for producing Tc-99m and has obtained a CE mark in Europe.